Tuesday, May 19, 2020

Amplyx Pharmaceuticals Adds $53M In Funding

San Diego-based Amplyx Pharmaceuticals has raised $53M in a Series C extension funding, bringing its Series C funding to over $90M, the comapny announced this morning. Amplyx--which is developing therapeutics for treating patients with compromised immune systems--said the funding was led by Sofinnova Inestments, and also included New Enterprise Associates, Lundbeckfonden Ventures, Arix Bioscience, Pappas Capital, RiverVest Venture Partners, 3×5 Partners, BioMed Ventures, along with Pfizer Inc. and Adage Capital Management. the company said the funding will go towards advancing clinical development of two innovative product candidates for the treatment of life-threatening diseases affecting patients with compromised immune systems. More information »